Navigation Links
Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings

MINNETONKA, Minn., April 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.  The meetings include the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington DC, May 1 - 4; the American Urological Association (AUA) Annual Meeting in Washington DC, May 14 -17; and the American Society of Colon & Rectal Surgeons (ASCRS) Annual Meeting in Vancouver, Canada, May 14 -18.  

"There is a growing body of clinical evidence in support of our Urgent PC and Macroplastique products," said David Kaysen, President and CEO of Uroplasty.  "This new data, along with previously published studies, confirms the efficacy and safety of both our products for the treatment of patients who suffer daily with overactive bladder or stress urinary incontinence."  

ACOG Presentations

  • Percutaneous Tibial Nerve Stimulation vs. Validated Sham in those Exposed to Pharmacologic Therapy presented by Dr. Denise Elser, Illinois Urogynecology, Oak Lawn, IL
  • Percutaneous Tibial Nerve Stimulation (PTNS) and the Effect on Fecal Incontinence* presented by Dr. Craig McCoy, Central Missouri Women's Healthcare, Marshall, MO

  • AUA Presentations

  • Insight into Percutaneous Tibial Nerve Stimulation: Critical Evaluation of the SUmiT Trial presented by Dr. Kenneth M. Peters, Beaumont Hospital, Royal Oak, MI
  • Long-term Durability of Polydimethylsiloxane Injection for Female Stress Urinary Incontinence Correlates with Histopathology presented by Dr. Gamal Ghoniem, Cleveland Clinic, Weston, FL
  • Treatment Interval Frequency of Percutaneous Tibial Nerve Stimulation: Preliminary Results from the STEP study presented by Dr. Scott A. MacDiarmid, Alliance Urology Specialists, Greensboro, NC

  • ASCRS Presentations

  • Percutaneous Tibial Nerve Stimulation and Effect on Fecal Incontinence: Results from Two Recent Overactive Bladder Trials* presented by Dr. Steven Siegel, Metro Urology, Woodbury, MN.  
  • A Prospective, Single-Blinded, Placebo-Controlled Study into the Role of Percutaneous and Transcutaneous Tibial Nerve Stimulation for Fecal Incontinence* presented by Dr. Anil George, St. Mark's Hospital, London, UK
  • Predictive Factors for Percutaneous Tibial Nerve Stimulation for Fecal Incontinence* presented by Dr. Anil George, St. Mark's Hospital, London

  • * Fecal incontinence is not currently an FDA cleared indication for PTNS in the U.S.

    About Uroplasty Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence.  We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency.  For more information on the company and its products, please visit Uroplasty, Inc. at

    Safe HarborThis press release contains forward-looking statements that reflect our best estimates regarding future events that could affect our financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report and on Form 10-K filed with the SEC.  We cannot be certain that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.Company Contact:Investor Relations Contacts:Media Contact:Uroplasty, Inc.

    EVC Group, Inc.

    EVC Group, Inc.David Kaysen, CEO

    Doug Sherk/Jenifer Kirtland

    Chris Gale/ Steve DiMattia(952) 426-6140

    (415) 896-2005


    SOURCE Uroplasty, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
    10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    Post Your Comments:
    (Date:10/13/2015)... 8, 2015 Research and Markets ( ... Anti-counterfeit Pharmaceuticals and Cosmetics Packaging - Market Opportunities and ... --> --> ... at a CAGR of 15.7% during 2015-2020 ... technology segment accounted for about 52% share in 2014 ...
    (Date:10/12/2015)... the United States . By early next ... --> the United States . By early next ... --> The University of Texas MD Anderson Cancer Center, Elekta ... (1.5 Tesla) MRI-guided linear accelerator in the United States ... in a non-clinical capacity. Royal Philips (NYSE: ...
    (Date:10/12/2015)... COSTA MESA, Calif. , Oct. 12, 2015 ... reaffirmed the accreditation of Harbor Compounding Pharmacy in ... accreditation is awarded in recognition of the pharmacy,s ... --> ... --> ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... GA (PRWEB) , ... October 13, 2015 , ... ... nonprofit promoting the establishment of telemedicine programs in communities throughout Georgia, along with ... announce the collective schedule for their regional telehealth summits for Fall 2015. ...
    (Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN ... orbital fracture when a teammate accidentally elbowed him in the left eye during the ... injury is just one of a series of setbacks, including a knee injury that ...
    (Date:10/13/2015)... ... October 13, 2015 , ... In an ... PediaPlex , a Southlake, Texas, child development and pediatric therapy center, is ... educating military families about their options for receiving this kind of care for ...
    (Date:10/13/2015)... Niguel, CA (PRWEB) , ... October 13, 2015 ... ... tools, announced the release of a new PDF automation tool to batch ... regulations, and business mandates with 100% document fidelity. , CADConverter eliminates the complexity ...
    (Date:10/13/2015)... , ... October 13, 2015 , ... ... winning programs Elder Care Doula Training and End of Life Doula Training. ... a holistic model, physically, spiritually and emotionally. Based on her #1 International ...
    Breaking Medicine News(10 mins):